Clinical Study of Ivonescimab for First-line Treatment of Metastatic Squamous NSCLC Patients
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05899608 |
Recruitment Status :
Recruiting
First Posted : June 12, 2023
Last Update Posted : May 6, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Non-Small Cell Lung Cancer | Biological: Ivonescimab Injection Biological: Pembrolizumab Injection | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 400 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Controlled, Multiregional Phase 3 Study of Ivonescimab Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (HARMONi-3) |
Actual Study Start Date : | October 26, 2023 |
Estimated Primary Completion Date : | September 30, 2027 |
Estimated Study Completion Date : | December 20, 2027 |
Arm | Intervention/treatment |
---|---|
Experimental: Arm A - Ivonescimab and chemotherapy
Subject will receive ivonescimab and chemotherapy
|
Biological: Ivonescimab Injection
Subject will receive ivonescimab and chemotherapy as an IV injection |
Active Comparator: Arm B - Pembrolizumab and chemotherapy
Subject will receive pembrolizumab and chemotherapy
|
Biological: Pembrolizumab Injection
Subject will receive pembrolizumab and chemotherapy as an IV injection |
- Overall Survival (OS) [ Time Frame: approximately 4 years ]Overall Survival (OS) in the ITT population
- Progression-Free Survival (PFS) [ Time Frame: approximately 4 years ]Progression-free survival (PFS) assessed by investigator based on RECIST v1.1
- Adverse Event (AE) [ Time Frame: From the subject signs the ICF to 30 days (AE) and 90 days (SAE related to ivonescimab/pembrolizumab ) after the last dose of study treatment or initiation of other anti-tumor therapy, whichever occurs first, up to 2 years. ]incidence and severity of adverse events (AEs) and clinically significant abnormal laboratory test results
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age ≥ 18 years old at the time of enrollment
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
- Expected life expectancy ≥ 3 months
- Metastatic (Stage IV) NSCLC
- Histologically or cytologically confirmed squamous NSCLC
- Tumor Proportion Score (TPS) with PD-L1 expression percent
- At least one measurable noncerebral lesion according to RECIST 1.1
- No prior systemic treatment for metastatic NSCLC
Exclusion Criteria:
- Histologic or cytopathologic evidence of the presence of small cell lung carcinoma, or non-squamous NSCLC histology.
- Known actionable genomic alterations in epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or ROS1 or genes for which first-line approved therapies are available
- Has received any prior therapy for NSCLC in the metastatic setting
- Tumor invasion, encasement of organs (e.g. heart, trachea, esophagus), or major blood vessels (e.g aorta, central veins), if poses a significant increased risk of bleeding.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05899608
Contact: Summit Clinical Trial Information | 1-833-256-0522 | medicalinformation@smmttx.com |
United States, California | |
Summit Therapeutics Research Center | Recruiting |
Los Angeles, California, United States, 90033 | |
Summit Therapeutics Research Center | Recruiting |
Los Angeles, California, United States, 90067 | |
Summit Therapeutics Research Center | Recruiting |
Sacramento, California, United States, 95817 | |
United States, Colorado | |
Summit Therapeutics Research Center | Recruiting |
Lone Tree, Colorado, United States, 80124 | |
United States, Florida | |
Summit Therapeutics Research Center | Recruiting |
Fort Myers, Florida, United States, 33901 | |
Summit Therapeutics Research Center | Recruiting |
Jacksonville, Florida, United States, 32256 | |
Summit Therapeutics Research Center | Recruiting |
Ocala, Florida, United States, 34474 | |
Summit Therapeutics Research Center | Recruiting |
Palm Bay, Florida, United States, 32901 | |
Summit Therapeutics Research Center | Recruiting |
Pensacola, Florida, United States, 32503 | |
Summit Therapeutics Research Center | Recruiting |
Plantation, Florida, United States, 33322 | |
Summit Therapeutics Research Center | Recruiting |
Saint Petersburg, Florida, United States, 33705 | |
Summit Therapeutics Research Center | Recruiting |
Tallahassee, Florida, United States, 32308 | |
Summit Therapeutics Research Center | Recruiting |
West Palm Beach, Florida, United States, 33401 | |
United States, Massachusetts | |
Summit Therapeutics Research Center | Recruiting |
Burlington, Massachusetts, United States, 01085 | |
United States, Michigan | |
Summit Therapeutics Research Center | Recruiting |
Detroit, Michigan, United States, 48202 | |
United States, Minnesota | |
Summit Therapeutics Research Center | Recruiting |
Saint Paul, Minnesota, United States, 55101 | |
United States, Montana | |
Summit Therapeutics Research Center | Recruiting |
Billings, Montana, United States, 59102 | |
United States, New York | |
Summit Therapeutics Research Center | Recruiting |
Albany, New York, United States, 12206 | |
United States, Ohio | |
Summit Therapeutics Research Center | Recruiting |
Cincinnati, Ohio, United States, 45242 | |
Summit Therapeutics Research Center | Recruiting |
Cleveland, Ohio, United States, 44195 | |
United States, Oregon | |
Summit Therapeutics Research Center | Recruiting |
Eugene, Oregon, United States, 97401 | |
United States, South Carolina | |
Summit Therapeutics Research Center | Recruiting |
Greenville, South Carolina, United States, 29605 | |
United States, Tennessee | |
Summit Therapeutics Research Center | Recruiting |
Nashville, Tennessee, United States, 37203 | |
United States, Texas | |
Summit Therapeutics Research Center | Recruiting |
Austin, Texas, United States, 78745 | |
Summit Therapeutics Research Center | Recruiting |
Dallas, Texas, United States, 75246 | |
Summit Therapeutics Research Center | Recruiting |
Harlingen, Texas, United States, 78550 | |
Summit Therapeutics Research Center | Recruiting |
Tyler, Texas, United States, 75702 | |
Summit Therapeutics Research Center | Recruiting |
Webster, Texas, United States, 77598 | |
United States, Virginia | |
Summit Therapeutics Research Center | Recruiting |
Norfolk, Virginia, United States, 23502 | |
Summit Therapeutics Research Center | Recruiting |
Reston, Virginia, United States, 20190 | |
United States, Washington | |
Summit Therapeutics Research Center | Recruiting |
Spokane, Washington, United States, 99202 | |
Canada, Ontario | |
Summit Therapeutics Research Center | Recruiting |
London, Ontario, Canada, N6A5W9 | |
Canada, Saskatchewan | |
Summit Therapeutics Research Center | Recruiting |
Regina, Saskatchewan, Canada, S4T7T1 |
Responsible Party: | Summit Therapeutics |
ClinicalTrials.gov Identifier: | NCT05899608 |
Other Study ID Numbers: |
SMT112-3003 |
First Posted: | June 12, 2023 Key Record Dates |
Last Update Posted: | May 6, 2024 |
Last Verified: | May 2024 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Lung Neoplasms Carcinoma, Non-Small-Cell Lung Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases |
Carcinoma, Bronchogenic Bronchial Neoplasms Pembrolizumab Antineoplastic Agents, Immunological Antineoplastic Agents Immune Checkpoint Inhibitors Molecular Mechanisms of Pharmacological Action |